Liminatus Pharma Inc. (NASDAQ:LIMN - Get Free Report)'s share price fell 7.1% on Wednesday . The stock traded as low as $2.99 and last traded at $3.02. 645,888 shares traded hands during trading, a decline of 72% from the average session volume of 2,273,840 shares. The stock had previously closed at $3.25.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised shares of Liminatus Pharma from a "sell" rating to a "hold" rating in a research note on Saturday.
Get Our Latest Stock Report on LIMN
Liminatus Pharma Stock Performance
The firm's 50 day moving average is $6.36.
About Liminatus Pharma
(
Get Free Report)
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Featured Stories
Before you consider Liminatus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liminatus Pharma wasn't on the list.
While Liminatus Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
